Tri-ethylene glycol modified class B and class C CpG conjugated gold nanoparticles for the treatment of lymphoma

Adam Yuh Lin; Jonathan Scott Rink; Reem Karmali; Jiahui Xu; Masha Kocherginsky; Colby Shad Thaxton; Leo I. Gordon

doi:10.1016/j.nano.2020.102290

Tri-ethylene glycol modified class B and class C CpG conjugated gold nanoparticles for the treatment of lymphoma

Adam Yuh Lin^*, Jonathan Scott Rink, Reem Karmali, Jiahui Xu, Masha Kocherginsky, Colby Shad Thaxton, Leo I. Gordon

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

CpG oligodeoxynucleotides (CpGs) can induce an anti-tumor immune response, but also uniquely cause direct lymphoma cytotoxicity. To improve the delivery and efficacy of CpGs, we utilized a tri-ethylene modified CpG conjugated gold nanoparticle (tmCpG NP) platform that is compatible with both class B and class C CpGs, to treat various types of lymphoma, including diffuse large B cell lymphoma, high-grade lymphoma, Burkitt's lymphoma, and mantle cell lymphoma. Both classes of tmCpG NPs reduced viability of human and murine lymphoma cells via apoptosis compared with free CpGs, while having no toxic effects on dendritic cells. TmCpG NPs increased CD19, CD20, and OX40 expression on the lymphoma cells. Overall, we introduced a stable tmCpG NP design that has significant anti-lymphoma effects.

Original language	English (US)
Article number	102290
Journal	Nanomedicine: Nanotechnology, Biology, and Medicine
Volume	30
DOIs	https://doi.org/10.1016/j.nano.2020.102290
State	Published - Nov 2020

Funding

Funding Sources: This work was supported by the Robert H. Lurie Comprehensive Cancer Center Cancer Center (RHLCCC) Support Grant ( NCI CA060553 ). AYL was supported by the American Society of Hematology Research Training Award for Fellows and the Northwestern University's Physician Scientist Training Program . LIG was supported by the RHLCCC Support Grant, Shannahan, Brookstone and Mander Foundations . This work was also supported by the Northwestern University RHLCCC Flow Cytometry Facility , and the Quantitative Data Sciences Core .

Keywords

Apoptosis
CpG oligodeoxynucleotides
Lymphoma therapy
Nanoparticles

ASJC Scopus subject areas

Bioengineering
Medicine (miscellaneous)
Molecular Medicine
Biomedical Engineering
General Materials Science
Pharmaceutical Science

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.nano.2020.102290

Cite this

@article{284d50f0fcca4ebf84c23b76db448fea,

title = "Tri-ethylene glycol modified class B and class C CpG conjugated gold nanoparticles for the treatment of lymphoma",

abstract = "CpG oligodeoxynucleotides (CpGs) can induce an anti-tumor immune response, but also uniquely cause direct lymphoma cytotoxicity. To improve the delivery and efficacy of CpGs, we utilized a tri-ethylene modified CpG conjugated gold nanoparticle (tmCpG NP) platform that is compatible with both class B and class C CpGs, to treat various types of lymphoma, including diffuse large B cell lymphoma, high-grade lymphoma, Burkitt's lymphoma, and mantle cell lymphoma. Both classes of tmCpG NPs reduced viability of human and murine lymphoma cells via apoptosis compared with free CpGs, while having no toxic effects on dendritic cells. TmCpG NPs increased CD19, CD20, and OX40 expression on the lymphoma cells. Overall, we introduced a stable tmCpG NP design that has significant anti-lymphoma effects.",

keywords = "Apoptosis, CpG oligodeoxynucleotides, Lymphoma therapy, Nanoparticles",

author = "Lin, {Adam Yuh} and Rink, {Jonathan Scott} and Reem Karmali and Jiahui Xu and Masha Kocherginsky and Thaxton, {Colby Shad} and Gordon, {Leo I.}",

note = "Funding Information: Funding Sources: This work was supported by the Robert H. Lurie Comprehensive Cancer Center Cancer Center (RHLCCC) Support Grant ( NCI CA060553 ). AYL was supported by the American Society of Hematology Research Training Award for Fellows and the Northwestern University's Physician Scientist Training Program . LIG was supported by the RHLCCC Support Grant, Shannahan, Brookstone and Mander Foundations . This work was also supported by the Northwestern University RHLCCC Flow Cytometry Facility , and the Quantitative Data Sciences Core . Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = nov,

doi = "10.1016/j.nano.2020.102290",

language = "English (US)",

volume = "30",

journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",

issn = "1549-9634",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Tri-ethylene glycol modified class B and class C CpG conjugated gold nanoparticles for the treatment of lymphoma

AU - Lin, Adam Yuh

AU - Rink, Jonathan Scott

AU - Karmali, Reem

AU - Xu, Jiahui

AU - Kocherginsky, Masha

AU - Thaxton, Colby Shad

AU - Gordon, Leo I.

N1 - Funding Information: Funding Sources: This work was supported by the Robert H. Lurie Comprehensive Cancer Center Cancer Center (RHLCCC) Support Grant ( NCI CA060553 ). AYL was supported by the American Society of Hematology Research Training Award for Fellows and the Northwestern University's Physician Scientist Training Program . LIG was supported by the RHLCCC Support Grant, Shannahan, Brookstone and Mander Foundations . This work was also supported by the Northwestern University RHLCCC Flow Cytometry Facility , and the Quantitative Data Sciences Core . Publisher Copyright: © 2020 Elsevier Inc.

PY - 2020/11

Y1 - 2020/11

N2 - CpG oligodeoxynucleotides (CpGs) can induce an anti-tumor immune response, but also uniquely cause direct lymphoma cytotoxicity. To improve the delivery and efficacy of CpGs, we utilized a tri-ethylene modified CpG conjugated gold nanoparticle (tmCpG NP) platform that is compatible with both class B and class C CpGs, to treat various types of lymphoma, including diffuse large B cell lymphoma, high-grade lymphoma, Burkitt's lymphoma, and mantle cell lymphoma. Both classes of tmCpG NPs reduced viability of human and murine lymphoma cells via apoptosis compared with free CpGs, while having no toxic effects on dendritic cells. TmCpG NPs increased CD19, CD20, and OX40 expression on the lymphoma cells. Overall, we introduced a stable tmCpG NP design that has significant anti-lymphoma effects.

AB - CpG oligodeoxynucleotides (CpGs) can induce an anti-tumor immune response, but also uniquely cause direct lymphoma cytotoxicity. To improve the delivery and efficacy of CpGs, we utilized a tri-ethylene modified CpG conjugated gold nanoparticle (tmCpG NP) platform that is compatible with both class B and class C CpGs, to treat various types of lymphoma, including diffuse large B cell lymphoma, high-grade lymphoma, Burkitt's lymphoma, and mantle cell lymphoma. Both classes of tmCpG NPs reduced viability of human and murine lymphoma cells via apoptosis compared with free CpGs, while having no toxic effects on dendritic cells. TmCpG NPs increased CD19, CD20, and OX40 expression on the lymphoma cells. Overall, we introduced a stable tmCpG NP design that has significant anti-lymphoma effects.

KW - Apoptosis

KW - CpG oligodeoxynucleotides

KW - Lymphoma therapy

KW - Nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=85090548735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090548735&partnerID=8YFLogxK

U2 - 10.1016/j.nano.2020.102290

DO - 10.1016/j.nano.2020.102290

M3 - Article

C2 - 32798731

AN - SCOPUS:85090548735

SN - 1549-9634

VL - 30

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

M1 - 102290

ER -

Tri-ethylene glycol modified class B and class C CpG conjugated gold nanoparticles for the treatment of lymphoma

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this